Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.
तुलना करने के लिए मीट्रिक्स | 382150 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध382150पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −10.2x | −9.4x | −0.5x | |
PEG अनुपात | 0.42 | −0.11 | 0.00 | |
क़ीमत/बुक | 5.3x | 3.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 96.2x | 11.1x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 37.0% | 51.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.9% | 8.5% | अनलॉक करें |